2',3'-cGAMP Sodium Salt
别名: 2'-3'-cyclic GMP-AMP Sodium, 2',3'-cGAMP Sodium
2',3'-cGAMP Sodium Salt (2'-3'-cyclic GMP-AMP Sodium)是响应哺乳动物细胞质中的DNA产生的，并能以高亲和力结合 STING，且有效地诱导 interferon-β (IFNβ)。2',3'-cGAMP 结合 STING 的Kd值为3.79 nM。
2',3'-cGAMP Sodium Salt Chemical Structure
CAS: 2734858-36-5
产品质控
批次：
纯度：
99.83%
99.83
常与2',3'-cGAMP Sodium Salt一起在实验中被使用的化合物
2',3'-cGAMP和Canagliflozin组合是骨肉瘤的新型疗法。
2',3'-cGAMP和Vadimezan (DMXAA)都能够将M2细胞重新教育为M1表型。
2',3'-cGAMPSodiumSalt和3',3'-cGAMP均能成熟的人单核细胞来源的DC，上调CD40/CD80/CD86/HLA-DR标记物水平。
diABZI STING agonist (Compound 3)
2',3'-cGAMP Sodium Salt和diABZI STING agonist (Compound 3)具有最有效的广谱抗病毒功能。
2',3'-cGAMP Sodium Salt相关产品
| 相关产品 | C-176 CCCP H-151 diABZI STING agonist (Compound 3) STING inhibitor C-178 C-171 G10 (STING agonist-1) MSA-2 | 点击展开 |
|---|---|---|
| 相关化合物库 | 激酶抑制剂库 FDA药物库 天然产物库 已知活性药物库-I 生物活性库Ⅱ | 点击展开 |
细胞实验数据示例
| 细胞系 | 实验类型 | 给药浓度 | 孵育时间 | 活性描述 | 文献信息 |
|---|---|---|---|---|---|
| PBMC | Function assay | 69.6 uM | 4 hrs | Agonist activity at STING in human PBMC cells assessed as increase in CXCL10 mRNA level at 69.6 uM measured after 4 hrs by qRT-PCR analysis | 31820985 |
| PBMC | Function assay | 1.39 to 139 uM | 4 hrs | Agonist activity at STING in human PBMC cells assessed as increase in IFNbeta release at 1.39 to 139 uM measured after 4 hrs by ELISA | 31820985 |
| PBMC | Function assay | 69.6 uM | 4 hrs | Agonist activity at STING in human PBMC cells assessed as increase in IFNbeta mRNA level at 69.6 uM measured after 4 hrs by qRT-PCR analysis | 31820985 |
| PBMC | Function assay | 69.6 uM | 4 hrs | Agonist activity at STING in human PBMC cells assessed as increase in IL6 mRNA level at 69.6 uM measured after 4 hrs by qRT-PCR analysis | 31820985 |
| PBMC | Function assay | 139 uM | 4 hrs | Agonist activity at STING in human PBMC cells assessed as increase in IL6 production at 139 uM measured after 4 hrs by ELISA | 31820985 |
| 293T | Function assay | 30 mins | Activation of recombinant human STING haplotype R71H/G230A/R293Q mutant expressed in 293T cells measured after 30 mins in presence of digitonin A by bright Glo-luciferase reporter gene assay, EC50 = 0.02 μM. | 31715099 | |
| 293T | Function assay | 30 mins | Activation of recombinant human wild-type STING expressed in 293T cells measured after 30 mins in presence of digitonin A by bright Glo-luciferase reporter gene assay, EC50 = 0.02 μM. | 31715099 | |
| 293T | Function assay | 30 mins | Activation of recombinant human STING haplotype G230A/R293Q mutant expressed in 293T cells measured after 30 mins in presence of digitonin A by bright Glo-luciferase reporter gene assay, EC50 = 0.04 μM. | 31715099 | |
| 293T | Function assay | 30 mins | Activation of recombinant human STING haplotype R293Q mutant expressed in 293T cells measured after 30 mins in presence of digitonin A by bright Glo-luciferase reporter gene assay, EC50 = 0.05 μM. | 31715099 | |
| 293T | Function assay | 30 mins | Activation of recombinant human STING haplotype R232H mutant expressed in 293T cells measured after 30 mins in presence of digitonin A by bright Glo-luciferase reporter gene assay, EC50 = 0.07 μM. | 31715099 | |
| 293T | Function assay | 7 hrs | Activation of recombinant human wild-type STING expressed in 293T cells incubated for 7 hrs in absence of digitonin A by bright Glo-luciferase reporter gene assay, EC50 = 13.7 μM. | 31715099 | |
| THP1 | Function assay | 20 hrs | Agonist activity at STING in human THP1 cells assessed as stimulation of IRF3 pathway measured after 20 hrs by luciferase reporter gene assay, EC50 = 38.6 μM. | 31820985 | |
| B16-OVA | Antitumor assay | Antitumor activity against mouse B16-OVA cells implanted in mouse assessed as tumour regression in injected flank at 10 ug administered intratumorally on day 6, 9 and 12 post implantation | 31500996 | ||
| B16-OVA | Antitumor assay | Antitumor activity against mouse B16-OVA cells implanted in mouse assessed as tumour regression in contralateral flank at 10 ug administered intratumorally on day 6, 9 and 12 post implantation | 31500996 | ||
| B16-OVA | Antitumor assay | Antitumor activity against mouse B16-OVA cells implanted in mouse assessed as higher number of mouse cured of tumors at 10 ug administered intratumorally on day 6, 9 and 12 post implantation | 31500996 | ||
| 点击查看更多细胞系数据 | |||||
生物活性
| 产品描述 | 2',3'-cGAMP Sodium Salt (2'-3'-cyclic GMP-AMP Sodium)是响应哺乳动物细胞质中的DNA产生的，并能以高亲和力结合 STING，且有效地诱导 interferon-β (IFNβ)。2',3'-cGAMP 结合 STING 的Kd值为3.79 nM。 | ||
|---|---|---|---|
| 靶点 |
|
化学信息&溶解度
| 分子量 | 718.37 | 分子式 | C20H22N10Na2O13P2 |
| CAS号 | 2734858-36-5 | SDF | -- |
| 密度 | g/mL | ||
| 储存条件(自收到货起) | 3年 -20°C 粉状 | ||
|
体外溶解度 |
DMSO : 100 mg/mL ( (139.2 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO) Water : 100 mg/mL (139.2 mM) Ethanol : Insoluble |
摩尔浓度计算器 |
|
体内溶解度 现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂 |
动物体内配方计算器 | ||||
实验计算
动物体内配方计算器（澄清溶液）
第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
mg/kg
g
μL
只
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
计算结果：
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；
体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH2O，混匀澄清。
体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。
注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
技术支持
在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。
如果有其他问题，请给我们留言。
* 必填项
Tags: buy 2',3'-cGAMP Sodium Salt | 2',3'-cGAMP Sodium Salt supplier | purchase 2',3'-cGAMP Sodium Salt | 2',3'-cGAMP Sodium Salt cost | 2',3'-cGAMP Sodium Salt manufacturer | order 2',3'-cGAMP Sodium Salt | 2',3'-cGAMP Sodium Salt distributor
